Bayer(US:BAYRY) Guo Ji Jin Rong Bao·2025-10-28 08:01Core Insights - Bayer views the China International Import Expo (CIIE) as a strategic platform for integrating into the Chinese economy and sharing development opportunities, highlighting its role as a catalyst for innovation and local collaboration [4][6] - The company has showcased over 50 first-time exhibits and secured nearly 40 significant contracts at the CIIE over the past seven years, demonstrating its commitment to the Chinese market [4][6] Group 1: CIIE Participation and Product Highlights - Bayer will present 26 highlight products at the 2025 CIIE, including 5 global debuts, 8 China debuts, and 13 first-time exhibits at the expo [5] - Notable products include the newly approved Eylea® 8mg for treating nAMD, which extends treatment intervals to four months, and the upgraded Bepanthen® B5 cream, providing triple protection for up to 16 hours [5] Group 2: Investment and Business Development in China - Bayer has experienced significant improvements in China's business environment, enhancing investment confidence and stability, making China a crucial strategic pillar for the company [6] - The company has made multiple breakthroughs in various sectors, including 19 innovative drugs approved and a new health consumer products center under construction with an investment of 750 million yuan, expected to be operational by 2028 [6][7] Group 3: Focus on Innovation and Sustainability - Bayer recognizes China's potential for innovation, transitioning from a follower to a source of biopharmaceutical innovation, supported by government initiatives and a vibrant R&D ecosystem [8] - The company plans to focus on digital solutions in healthcare, integrated product-service ecosystems in consumer health, and regenerative agriculture technologies in crop science [8]